517 related articles for article (PubMed ID: 24657122)
41. Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.
Cooper B; DeTora L; Stoddard J
Expert Rev Vaccines; 2011 Jan; 10(1):21-33. PubMed ID: 21162617
[TBL] [Abstract][Full Text] [Related]
42. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
43. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
Quiambao BP; Jain H; Bavdekar A; Dubey AP; Kolhe D; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2016 Aug; 12(8):2162-2168. PubMed ID: 27152501
[TBL] [Abstract][Full Text] [Related]
44. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
[TBL] [Abstract][Full Text] [Related]
45. Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age.
Vesikari T; Peyrani P; Webber C; Van Der Wielen M; Cheuvart B; De Schrevel N; Aris E; Cutler M; Li P; Perez JL
Hum Vaccin Immunother; 2020 Jun; 16(6):1280-1291. PubMed ID: 32598244
[TBL] [Abstract][Full Text] [Related]
46. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study.
Baccarini CI; Simon MW; Brandon D; Christensen S; Jordanov E; Dhingra MS
Pediatr Infect Dis J; 2020 Oct; 39(10):955-960. PubMed ID: 32852352
[TBL] [Abstract][Full Text] [Related]
47. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.
Keyserling H; Papa T; Koranyi K; Ryall R; Bassily E; Bybel MJ; Sullivan K; Gilmet G; Reinhardt A
Arch Pediatr Adolesc Med; 2005 Oct; 159(10):907-13. PubMed ID: 16203934
[TBL] [Abstract][Full Text] [Related]
48. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.
Read RC; Dull P; Bai X; Nolan K; Findlow J; Bazaz R; Kleinschmidt A; McCarthy M; Wang H; Toneatto D; Borrow R
Vaccine; 2017 Jan; 35(3):427-434. PubMed ID: 27912986
[TBL] [Abstract][Full Text] [Related]
49. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age.
Black S; Klein NP; Shah J; Bedell L; Karsten A; Dull PM
Vaccine; 2010 Jan; 28(3):657-63. PubMed ID: 19895922
[TBL] [Abstract][Full Text] [Related]
50. A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.
Borja-Tabora CFC; Peyrani P; Webber C; Van der Wielen M; Cheuvart B; De Schrevel N; Bianco V; Aris E; Cutler M; Li P; Perez JL
BMC Infect Dis; 2020 Jun; 20(1):426. PubMed ID: 32552685
[TBL] [Abstract][Full Text] [Related]
51. Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth.
Warshaw MG; Siberry GK; Williams P; Decker MD; Jean-Philippe P; Lujan-Zilbermann J
J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e69-e74. PubMed ID: 28339668
[TBL] [Abstract][Full Text] [Related]
52. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America.
Stamboulian D; Lopardo G; Lopez P; Cortes-Barbosa C; Valencia A; Bedell L; Karsten A; Dull PM
Int J Infect Dis; 2010 Oct; 14(10):e868-75. PubMed ID: 20655261
[TBL] [Abstract][Full Text] [Related]
53. Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study.
Dbaibo G; Tinoco Favila JC; Traskine M; Jastorff A; Van der Wielen M
Vaccine; 2018 Jun; 36(28):4102-4111. PubMed ID: 29784470
[TBL] [Abstract][Full Text] [Related]
54. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).
Østergaard L; Van der Wielen M; Bianco V; Miller JM
Int J Infect Dis; 2013 Mar; 17(3):e173-6. PubMed ID: 23246368
[TBL] [Abstract][Full Text] [Related]
55. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
Borja-Tabora CF; Montalban C; Memish ZA; Boutriau D; Kolhe D; Miller JM; Van der Wielen M
BMC Infect Dis; 2015 Oct; 15():409. PubMed ID: 26437712
[TBL] [Abstract][Full Text] [Related]
56. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.
Ilyina N; Kharit S; Namazova-Baranova L; Asatryan A; Benashvili M; Tkhostova E; Bhusal C; Arora AK
Hum Vaccin Immunother; 2014; 10(8):2471-81. PubMed ID: 25424958
[TBL] [Abstract][Full Text] [Related]
57. Persistence of bactericidal antibodies 4 years after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D).
Robertson CA; Hedrick J; Bassily E; Greenberg DP
Vaccine; 2019 Feb; 37(8):1016-1020. PubMed ID: 30670301
[TBL] [Abstract][Full Text] [Related]
58. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.
Vesikari T; Forstén A; Boutriau D; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2012 Dec; 8(12):1892-903. PubMed ID: 23032159
[TBL] [Abstract][Full Text] [Related]
59. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.
Khatami A; Snape MD; Davis E; Layton H; John T; Yu LM; Dull PM; Gill CJ; Odrjlin T; Dobson S; Halperin SA; Langley JM; McNeil SA; Pollard AJ
Vaccine; 2012 Apr; 30(18):2831-8. PubMed ID: 22394992
[TBL] [Abstract][Full Text] [Related]
60. Immunogenicity of MenACWY-CRM in Korean Military Recruits: Influence of Tetanus-Diphtheria Toxoid Vaccination on the Vaccine Response to MenACWY-CRM.
Kim HW; Park IH; You S; Yu HT; Oh IS; Sung PS; Shin EC; Kim KH
Yonsei Med J; 2016 Nov; 57(6):1511-6. PubMed ID: 27593883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
